Nomir Heading

Wound Care

Wound care and management, including the treatment of diabetic foot ulcers, represent a $3.3 billion market. Approximately 7 percent of the U.S. population, or 20.8 million people (i)suffer from diabetes. An estimated 15 percent of diabetics will develop an ulcer during the course of their disease (ii). Infection of these ulcers is the most frequent cause of diabetic hospitalizations and is the biggest risk factor for lower extremity amputation, contributing to the high morbidity and mortality of the disease. Additionally, these wounds cannot heal normally when bacteria proliferate. Based on encouraging results in pilot MRSA studies, Nomir believes that Noveon® therapy may not only address underlying wound infections, but may also, as a result, promote wound healing.

Nomir has initiated a proof-of-concept trial utilizing Noveon therapy for the treatment of diabetic foot ulcers. The primary objective of the trial is to test the efficacy and safety of Noveon in reducing bio-burden from diabetic foot ulcers. A secondary measure of the trial is to demonstrate satisfactory or improved healing of the ulcer.

(i) American Diabetes Association
(ii) Health Advances Report-July 2008